Gain Therapeutics (GANX) Income towards Parent Company (2020 - 2025)
Historic Income towards Parent Company for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to -$5.3 million.
- Gain Therapeutics' Income towards Parent Company fell 1780.49% to -$5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$21.9 million, marking a year-over-year decrease of 115.4%. This contributed to the annual value of -$22.9 million for FY2024, which is 163.48% down from last year.
- According to the latest figures from Q3 2025, Gain Therapeutics' Income towards Parent Company is -$5.3 million, which was down 1780.49% from -$5.8 million recorded in Q2 2025.
- Gain Therapeutics' 5-year Income towards Parent Company high stood at -$2.5 million for Q1 2021, and its period low was -$8.1 million during Q2 2024.
- Over the past 5 years, Gain Therapeutics' median Income towards Parent Company value was -$4.7 million (recorded in 2022), while the average stood at -$4.9 million.
- As far as peak fluctuations go, Gain Therapeutics' Income towards Parent Company crashed by 55457.15% in 2021, and later soared by 2866.23% in 2025.
- Quarter analysis of 5 years shows Gain Therapeutics' Income towards Parent Company stood at -$3.2 million in 2021, then crashed by 45.17% to -$4.7 million in 2022, then fell by 7.25% to -$5.0 million in 2023, then decreased by 25.32% to -$6.3 million in 2024, then increased by 15.89% to -$5.3 million in 2025.
- Its Income towards Parent Company stands at -$5.3 million for Q3 2025, versus -$5.8 million for Q2 2025 and -$4.5 million for Q1 2025.